Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

MINIMALINVASIV KIRURGI FÖR GRAD III HEMORROJDER

17 september 2026 uppdaterad av: Ignacio Fernandez Hurtado, Hospital Son Llatzer

Prospektiv observationsstudie för att bedöma reproducerbarheten av minimalt invasiv kirurgi vid slutande exciserande hemorroidoperation: Fas 2A i I DEAL-ramverket

Hemorrhoids are vascular-elastic structures of the anal canal that contribute to continence. Their enlargement and descent lead to symptoms such as rectal bleeding and the sensation of anal swelling, known as hemorrhoidal syndrome. In advanced cases (Goligher Grade III-IV), surgery is the only effective treatment. Closed excisional hemorrhoidectomy (CEH), based on the Ferguson technique, is one of the standard procedures. Although effective in the long term, it causes severe postoperative pain. Minimally invasive surgery (MIS) employs enhanced visualization devices to improve surgical precision and reduce tissue damage. While widely used in specialties with small surgical fields, it has not yet been explored in anal surgery. Its advantages include reduced tissue injury and improved healing, although it presents a learning curve and an initially longer surgical time. The IDEAL framework evaluates surgical innovations in five stages: Idea, Development, Exploration, Evaluation, and Long-Term Study. The IDEAL phase 2a is aimed at the optimization and technical definition of surgical innovation with a focus on continuous improvement based on real clinical practice, laying the foundation for broader and more rigorous subsequent studies.

Since no previous studies on the application of MIS in CEH have been found, the investigators propose a study within Stage 2A of the IDEAL model to assess the reproducibility of this technique. The investigators believe its incorporation into closed excisional hemorrhoidectomy could result in less postoperative pain and faster patient recovery.

Studieöversikt

Studietyp

Observationell

Inskrivning (Beräknad)

50

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Ignacio Fernandez-Hurtado, Colorectal Surgeon
  • Telefonnummer: 2134 +34 871202000
  • E-post: ifernandez@hsll.es

Studieorter

    • Balearic Islands
      • Palma, Balearic Islands, Spanien, 07190
        • Rekrytering
        • Hospital Son Llatzer
        • Kontakt:
          • Ignacio Fernandez-Hurtado, Colorectal Surgeon
          • Telefonnummer: 2134 +34 871 202000
          • E-post: ifernandez@hsll.es

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients attending the Surgery Department of our Hospital

Beskrivning

Inclusion Criteria:

  • Age over 18 years
  • Grade III/IV hemorrhoids
  • Indication for CEH surgery
  • Signed written informed consent

Exclusion Criteria:

  • Acute hemorrhoidal disease (thrombosis)
  • Previous hemorrhoid surgery
  • Coexistence of anal fissure
  • Coexistence of perianal fistula
  • Coexistence of rectal or anal prolapse
  • Active inflammatory bowel disease
  • Active anal or colorectal cancer
  • Language barrier or difficulty in oral and/or written comprehension

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Grade III / IV hemorrhoids

Patients with symptomatic grade III/IV hemorrhoids who consent to surgical intervention

The investigators propose applying minimally invasive surgery in closed excisional hemorrhoidectomy (CEH) , the most effective technique for treating advanced hemorrhoidal disease. The investigators believe this approach will reduce postoperative pain and improve recovery while maintaining the excellent outcomes of CEH. The investigator's hypothesis is based on the reduced tissue trauma and increased precision provided by minimally invasive surgery.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Technical Reproducibility of Surgery
Tidsram: 30 postoperative days

ince no studies using this approach were found in the literature, the investigators propose a study to assess the reproducibility of implementing this technique following the guidelines of the IDEAL framework. In this study, the investigators propose Stage 2A. The measurement tool will be the systematic documentation of technical modifications.

30 postoperative days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Adverse events in treated patients
Tidsram: 30 postoperative days

Collect the adverse effects that occur during the operative period and within the first 30 postoperative days. Filter those attributable to the use of the minimally invasive approach. Analyze the causes and the technical steps that should be performed or omitted to avoid them. As measurement tools, the Clavien-Dindo scale and the Comprehensive Complication Index (CCI) will be used. The CCI is an index that uses the Clavien-Dindo scale and is calculated with a mathematical formula available at www.assessurgery.com

30 postoperative days
Postoperative pain
Tidsram: The first 14 postoperative days

Postoperative pain will be evaluated using the Visual Analogue Scale (VAS), a validated tool ranging from 0 (no pain) to 10 (worst imaginable pain). Patients will self-assess their baseline pain and pain following defecation at predefined intervals: postoperative days 4, 7, and 14.

The first 14 postoperative days
Hemorrhoidal disease symptom score
Tidsram: one postoperative year

A score that defines the frecuency of pain, pruritus, bleeding, soiling and prolapse. Score 0 to 20. Higher scores mean a worse outcome.

one postoperative year
Short Health Scale in hemorrhoidal disease
Tidsram: One year postoperative

A subjective scale which defines symptom intensity, the patient's worrying and the role in impairment of daily activity. Score 4 to 28. Higher scores mean a worse outcome

One year postoperative
Total number of postoperative analgesics
Tidsram: 14 postoperative days

The total number of analgesic doses taken by the patient during the first 14 postoperative days will be recorded as a numeric variable

14 postoperative days
Clinical Failure Rate
Tidsram: one year postoperative

Clinical failure rate (CFR) is defined by the difference in haemorrhoidal symptoms according to Haemorrhoidal Disease Symptom Score and haemorrhoidal disease-related quality of life according to Short Health Scale adapted for Haemorrhoidal Disease comparing baseline and 1-year values. This difference was calculated using the following formula: (baseline Haemorrhoidal Disease Symptom Score - postoperative Haemorrhoidal Disease Symptom Score )/ baseline Haemorrhoidal Disease Symptom Score × 100. The change in quality of life related to haemorrhoidal disease was calculated using the following formula: (baseline Short Health Scale adapted for Haemorrhoidal Disease - postoperative Short Health Scale adapted for Haemorrhoidal Disease.)/baseline Short Health Scale adapted for Haemorrhoidal Disease. × 100. CFR was positive when both criteria showed a ≤50% difference.

one year postoperative

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 juni 2026

Primärt slutförande (Beräknad)

1 december 2026

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

10 april 2026

Först inskickad som uppfyllde QC-kriterierna

10 april 2026

Första postat (Faktisk)

16 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • HEM CLOSE IDEAL 2A

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera